LIFT BioSciences
Generated by Meeveem AI
"Pioneering neutrophil cell therapies to kill solid tumours and restore immune response"
London
•11 - 50 Employees
•Biotechnology
About LIFT BioSciences
LIfT BioSciences develops first-in-class Immunomodulatory Alpha Neutrophil (IMAN) cell therapies for hard-to-treat solid cancers. The off-the-shelf allogeneic platform harnesses neutrophils' natural ability to infiltrate tumours, directly kill cancer cells, and orchestrate broader immune responses, providing an antigen-independent treatment for patients who progress on standard therapies. Backed by deep neutrophil biology expertise and scalable manufacturing, LIfT advances a differentiated pipeline addressing cervical and head & neck cancers. The upcoming Phase 1 clinical study will assess IMANs' safety, biodistribution, and anti-tumour activity, moving closer to delivering complete remission across multiple solid tumour types.
25
Team Members
2016
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where every patient with solid tumours achieves complete remission through accessible, off-the-shelf neutrophil cell therapies that overcome cancer's most resistant escape mechanisms
Our Mission
Develops the world's first mass-produced neutrophil cell bank to deliver immuno-oncology therapies for complete remission in solid tumours